Balyasny Asset Management
ANRO icon

Balyasny Asset Management’s Alto Neuroscience ANRO Stock Holding History

Balyasny Asset Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,111
Closed -$722K – 3581
2026
Q1 		$722K Buy
32,111
+20,991
+189% +$389K ﹤0.01% 2215
2025
Q4 		$198K Buy
+11,120
New +$140K ﹤0.01% 2887

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Balyasny Asset Management's ANRO Position: Q2 2026 in Review

Balyasny Asset Management sold out of Alto Neuroscience (ANRO) in Q2 2026, closing a stake of 32,111 shares — an estimated $722K sold.

Balyasny Asset Management first reported a position in ANRO in Q4 2025 and held it in 2 quarters. The position peaked at $722K in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Balyasny Asset Management reported no remaining Alto Neuroscience position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 32,111 Alto Neuroscience shares in Q2 2026, an estimated $722K.
  • Balyasny Asset Management first reported a position in Alto Neuroscience in Q4 2025 and held it in 2 quarters.
  • Balyasny Asset Management's Alto Neuroscience position peaked at $722K in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.